CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,293,720 | +1112.7% | 312,499 | +634.8% | 0.00% | – |
| Q2 2023 | $766,355 | +50218.8% | 42,528 | -55.1% | 0.00% | -100.0% |
| Q1 2023 | $1,523 | -85.5% | 94,807 | -83.5% | 0.00% | -83.3% |
| Q4 2022 | $10,531 | -99.8% | 575,488 | +78.9% | 0.01% | +50.0% |
| Q3 2022 | $6,319,000 | -33.5% | 321,752 | -36.8% | 0.00% | -33.3% |
| Q2 2022 | $9,499,000 | +83.2% | 509,330 | +115.7% | 0.01% | +100.0% |
| Q1 2022 | $5,184,000 | +453.8% | 236,160 | +616.5% | 0.00% | – |
| Q4 2021 | $936,000 | +267.1% | 32,959 | +172.1% | 0.00% | – |
| Q3 2021 | $255,000 | +24.4% | 12,112 | -16.7% | 0.00% | – |
| Q4 2020 | $205,000 | -89.6% | 14,538 | -87.1% | 0.00% | -100.0% |
| Q2 2020 | $1,980,000 | +337.1% | 113,034 | +526.5% | 0.00% | +200.0% |
| Q4 2019 | $453,000 | -45.4% | 18,041 | -67.3% | 0.00% | 0.0% |
| Q3 2019 | $829,000 | +310.4% | 55,149 | +520.5% | 0.00% | – |
| Q1 2019 | $202,000 | – | 8,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |